MA52962B1 - Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 - Google Patents

Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Info

Publication number
MA52962B1
MA52962B1 MA52962A MA52962A MA52962B1 MA 52962 B1 MA52962 B1 MA 52962B1 MA 52962 A MA52962 A MA 52962A MA 52962 A MA52962 A MA 52962A MA 52962 B1 MA52962 B1 MA 52962B1
Authority
MA
Morocco
Prior art keywords
antibodies
methods
cd3xmuc16
treating cancer
bispecific
Prior art date
Application number
MA52962A
Other languages
English (en)
Other versions
MA52962A (fr
Inventor
Alison CRAWFORD
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA52962A publication Critical patent/MA52962A/fr
Publication of MA52962B1 publication Critical patent/MA52962B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Les méthodes selon la présente invention comprennent l'administration, à un sujet qui en a besoin, d'une quantité thérapeutiquement efficace d'un anticorps ou d'un fragment de celui-ci de liaison à l'antigène qui se lie spécifiquement au récepteur de mort programmée 1 (PD-1) en association avec une quantité thérapeutiquement efficace d'un anticorps bispécifique qui se lie spécifiquement à la mucine 16 (MUC16) et à CD3.
MA52962A 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 MA52962B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688251P 2018-06-21 2018-06-21
PCT/US2019/038163 WO2019246356A1 (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP19739472.9A EP3810281B1 (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Publications (2)

Publication Number Publication Date
MA52962A MA52962A (fr) 2021-04-28
MA52962B1 true MA52962B1 (fr) 2024-10-31

Family

ID=67254001

Family Applications (2)

Application Number Title Priority Date Filing Date
MA52962A MA52962B1 (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA71708A MA71708A (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA71708A MA71708A (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Country Status (26)

Country Link
US (1) US11254752B2 (fr)
EP (2) EP4424712A3 (fr)
JP (1) JP7403480B2 (fr)
KR (1) KR102870971B1 (fr)
CN (1) CN112312970B (fr)
AU (1) AU2019290170B2 (fr)
BR (1) BR112020025476A2 (fr)
CA (1) CA3103887A1 (fr)
CL (1) CL2020003256A1 (fr)
DK (1) DK3810281T3 (fr)
EA (1) EA202190088A1 (fr)
ES (1) ES2984972T3 (fr)
FI (1) FI3810281T3 (fr)
HU (1) HUE067985T2 (fr)
IL (1) IL279251B2 (fr)
MA (2) MA52962B1 (fr)
MX (2) MX2020013905A (fr)
MY (1) MY202134A (fr)
PH (1) PH12020552115A1 (fr)
PL (1) PL3810281T3 (fr)
PT (1) PT3810281T (fr)
RS (1) RS65886B1 (fr)
SG (1) SG11202012137UA (fr)
TW (2) TW202504917A (fr)
WO (1) WO2019246356A1 (fr)
ZA (1) ZA202007599B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
JP2023539525A (ja) * 2020-09-02 2023-09-14 ジェンマブ エー／エス 抗体療法
NL2027601B1 (en) * 2021-02-19 2022-09-19 Crm Therapeutics B V Target mediated endocytotic drug delivery
CA3202891A1 (fr) 2021-01-28 2022-08-04 Kara Olson Compositions et methodes de traitement du syndrome de liberation de cytokines
CN117015394A (zh) * 2021-03-12 2023-11-07 博际生物医药科技(杭州)有限公司 结合人TGFβ和PD-L1的双功能分子及其应用
EP4308160A4 (fr) * 2021-03-18 2025-07-02 Memorial Sloan Kettering Cancer Center Méthodes de traitement du cancer gynécologique à l'aide d'une polythérapie avec des anticorps multispécifiques anti-muc16 x cd3 et des inhibiteurs de vegf
CN117320700A (zh) * 2021-04-02 2023-12-29 瑞泽恩制药公司 含有抗muc16 x抗cd3双特异性抗体的稳定制剂
JPWO2023033022A1 (fr) 2021-08-31 2023-03-09
MX2024006187A (es) * 2021-11-24 2024-08-14 Regeneron Pharma Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
MX2024008055A (es) * 2022-01-07 2024-09-06 Regeneron Pharma Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.
US20250092135A1 (en) * 2022-01-10 2025-03-20 Nanjing Leads Biolabs Co., Ltd. Antibody and use thereof
WO2023176881A1 (fr) * 2022-03-16 2023-09-21 第一三共株式会社 Combinaison d'une molécule multi-spécifique et d'un inhibiteur de point de contrôle immunitaire
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
WO2018099539A1 (fr) 2016-11-29 2018-06-07 Horst Lindhofer Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations

Also Published As

Publication number Publication date
FI3810281T3 (fi) 2024-08-14
AU2019290170A1 (en) 2021-01-07
EP3810281B1 (fr) 2024-07-24
EP4424712A2 (fr) 2024-09-04
IL279251B1 (en) 2025-11-01
IL279251B2 (en) 2026-03-01
CL2020003256A1 (es) 2021-04-30
BR112020025476A2 (pt) 2021-03-16
PL3810281T3 (pl) 2024-11-04
AU2019290170B2 (en) 2026-04-02
MX2020013905A (es) 2021-03-09
CN112312970B (zh) 2025-05-23
MA71708A (fr) 2025-05-30
PT3810281T (pt) 2024-08-02
CN112312970A (zh) 2021-02-02
KR102870971B1 (ko) 2025-10-16
US20190389966A1 (en) 2019-12-26
TW202504917A (zh) 2025-02-01
MY202134A (en) 2024-04-05
EP3810281A1 (fr) 2021-04-28
ZA202007599B (en) 2025-02-26
DK3810281T3 (da) 2024-08-19
SG11202012137UA (en) 2021-01-28
RS65886B1 (sr) 2024-09-30
IL279251A (en) 2021-01-31
PH12020552115A1 (en) 2021-08-02
JP7403480B2 (ja) 2023-12-22
EP4424712A3 (fr) 2024-11-13
TWI890661B (zh) 2025-07-21
JP2021528423A (ja) 2021-10-21
MX2025008444A (es) 2025-08-01
HUE067985T2 (hu) 2024-12-28
ES2984972T3 (es) 2024-10-31
US11254752B2 (en) 2022-02-22
WO2019246356A1 (fr) 2019-12-26
MA52962A (fr) 2021-04-28
KR20210023981A (ko) 2021-03-04
EA202190088A1 (ru) 2021-03-22
CA3103887A1 (fr) 2019-12-26
TW202005985A (zh) 2020-02-01

Similar Documents

Publication Publication Date Title
MA44146B1 (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
MX2025008444A (es) Uso de un anticuerpo anti-pd-1 y un anticuerpo anti-cd3 x muc16 biespecifico para el tratamiento de un tumor que expresa muc16
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
Muthumani et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
Hoseini et al. A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA44234B1 (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA33387B1 (fr) Polypeptides et procede de traitement
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
MX2023010764A (es) Anticuerpo anti componente del complemento 1s (c1s).
MX2021003867A (es) Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MA59827B1 (fr) Anticorps anti-pd-1
MA53186B2 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
MX2024008055A (es) Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.